NEW YORK (GenomeWeb News) – Caprion Proteomics said today that it is working with Applied Biosystems to verify and validate protein biomarker candidates for use in clinical settings.
Caprion said it is using the Life Technologies division's QTRAP technology to develop and deploy multiple reaction monitoring (MRM) assays to validate biomarker candidates. The QTRAP technology is used to integrate quantitative and qualitative analysis through the MIDAS workflow and fast MRM assay development and quantitative results, said Caprion.
In cases where there are no commercial assays for a set of biomarker candidates, the MRM technique "offers a faster and more cost-effective alternative to established enzyme-linked immunosorbant assay (ELISA) development approaches," the company said. The company said this approach potentially could be used to generate "significant value from the scores of genomics, proteomics, and other biomarker candidates that have not yet progressed to the validation stage."
"The technology has evolved to the point where working with organizations, such as Caprion, is more rapidly unlocking the potential of protein biomarkers and helping to advance the proteomics field," David Hicks, senior director of Applied Biosystems' pharmaceutical and proteomics business, said in a statement.